GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD GlaxoSmithKline plc ...
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced positive headline results from a phase IIIb study – Salford Lung Study – on Relvar Ellipta (100/25mcg; furoate/vilanterol) for the ...
The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone ...
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate ...
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
A "ground-breaking" UK study has shown that GlaxoSmithKline's Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results